General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

The Malaria Initiative

The Novartis Malaria Initiative focuses on improving access to treatment, helping communities in malaria-endemic countries deliver better healthcare and investing in research and development into the next generation of antimalarials. Over the past decade, the initiative has become one of the largest access-to-medicine programs in the healthcare industry, measured by the number of patients reached annually.

Since 2001, working with a range of organizations, we have provided more than 700 million treatments for adults and children, without profit, to more than 60 malaria-endemic countries, contributing to a significant reduction of the death toll from malaria, mostly infants and children. We are proud of the remarkable public health milestones these collaborations have helped to achieve.

1994
Innovative collaboration starts between Novartis and Chinese partners
1997
Daniel Vasella, Honorary Chairman of the Board of Novartis, commits to make the fight against malaria a key aspect of the company’s access-to-medicine programs
1998-1999
First regulatory approvals for artemether-lumefantrine in Africa (Gabon), Switzerland and Europe (UK)
1999
Launch of artemether-lumefantrine, the first ACT brought to market in a fixed-dose form
2001
Collaboration with the WHO to supply artemether-lumefantrine without profit to the public sector
2002
Artemether-lumefantrine is the first ACT listed on the WHO's Model List of Essential Medicines
2005-2006
Subsequent production scale-up to 100 million treatment capacity per year
2006
Start of best practice sharing workshops with national malaria control program managers
2006-2009
Price more than halved thanks to economies of scale
2009
Healthcare Compliance Packaging Council Award
2009
  • Launch of Dispersible artemether-lumefantrine with MMV
  • Artemether-lumefantrine is the first ACT approved by the US FDA
2010
  • Prix Galien USA
  • World Business and Development Award, United Nations
  • Award for Corporate Social Responsibility by the Association of Strategic Alliance Professionals
2011
Wall Street Journal Technology Innovation Award for SMS for Life
2011
GBC Business Action on Health Awards for SMS for Life
2012
SMS for Life honored with a catalytic grant from The Innovation Working Group and the Wall Street Journal’s Technology Innovation Award in the Health-Care IT category
2012
New private-sector access program launched to make high-quality antimalarials affordable to patients in malaria-endemic countries
2013
Novartis joins forces with Malaria No More on the Power of One campaign. Malaria No More honors Novartis with first annual Malaria Award for Private Sector Excellence and with Global Corporate Citizenship Award
2013
600 million Novartis ACT treatments delivered without profit to patients since 2001, of which 200 million dispersible pediatric treatments since 2009
2013
Two completely new antimalarial compounds move into development and a third new malaria drug target is discovered